Could it be more obvious? Leo would not need to do IBD first and then fund B OM if the B OM data were that good. Someone would pick up the bill and we woulda had a deal over a year ago.
He's leading you down a rabbit hole. Our first deal and focus is in UP negotiations (in my opinion not our only deal) will be to develop and commercialize Brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. Our first deal will be huge for this company. We have something here to celebrate.